Enjoy complimentary customisation on priority with our Enterprise License!
The anorexiants market size is forecast to increase by USD 1.02 billion and is estimated to grow at a CAGR of 4.5% between 2023 and 2028. The global obesity epidemic has led to a significant increase in demand for effective weight loss solutions. In response, the healthcare industry is witnessing a surge in innovation, with a focus on developing advanced combination therapies. These therapies often incorporate a multi-faceted approach, combining medication, diet, and exercise. Additionally, government initiatives to improve healthcare infrastructure are creating a conducive environment for the growth of this market. For instance, the U.S. National Institutes of Health has launched several research programs to develop new obesity treatments. These trends are expected to drive the growth of the obesity treatment market in the coming years.
For More Highlights About this Report, Request Free Sample
The Market refers to the segment of the pharmaceutical industry that produces drugs used for weight loss. Anorexiants are pharmaceutical compounds designed to suppress appetite and increase metabolism, making them effective in managing obesity and associated health conditions such as cardiovascular diseases, diabetes, and hypertension. Sedentary lifestyles, physical inactivity, and unhealthy dietary habits have fueled the demand for anorexiants. Two main types of anorexiants exist: Catecholamines Anorexiants and Serotonin Anorexiants. Catecholamines Anorexiants stimulate the sympathetic nervous system, increasing heart rate and blood pressure, while Serotonin Anorexiants affect the brain's appetite regulation. Anorexiants are available in various forms, including oral tablets and capsules, as well as subcutaneous injections. The market caters to various end-users, including hospitals, specialty clinics, and homecare settings. Anorexiants are also used in the treatment of conditions like ADHD, Dravet Syndrome, and Lennox Gastaut Syndrome. The World Health Organization (WHO) emphasizes the importance of addressing obesity and related health issues, driving the growth of the market. CNS stimulants, such as amphetamines and phentermine, are commonly used oral anorexiants, while subcutaneous anorexiants like leptin are injected to stimulate weight loss. Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
The growing obese population is notably driving market growth. Obesity, a significant public health issue, is linked to various chronic conditions including diabetes, hypertension, and cancer. The global prevalence and incidence of obesity are alarmingly high, particularly in the US, due to the limited effectiveness of existing treatments. Factors contributing to obesity include sedentary lifestyles, inactivity, and unhealthy eating habits.
Moreover, these behaviors can lead to complications such as cardiovascular diseases, musculoskeletal issues, and certain types of cancer, including breast, colon, and endometrial. Genetics and family lifestyle also play a role in obesity development. Thus, such factors are driving the growth of the market during the forecast period.
Research and approval of new drugs is the key trend in the market. Anorexiants, a category of anti-obesity drugs, are gaining significant attention due to their potential to alleviate the suffering of millions of individuals battling obesity. These medications, which include Lorcaserin, Naltrexone, Orlistat, and Liraglutide, among others, function by targeting the limbic parts of the brain, thereby promoting satiety and reducing appetite.
Moreover, in June 2021, the US Food and Drug Administration (FDA) approved a new drug, semaglutide, for weight loss among overweight or obese adults. This injectable medication, marketed as Wegovy, is administered once a week and induces weight loss by increasing feelings of fullness and reducing hunger, enabling users to consume fewer calories. Thus, such trends will shape the growth of the market during the forecast period.
The low safety and tolerability profile of anti-obesity drugs is the major challenge that affects the growth of the market. The prevalence of obesity and related chronic diseases, such as breast cancer, colon cancer, Type 2 diabetes, endometrial cancer, cardiovascular disease, and musculoskeletal issues, is on the rise due to factors including family lifestyle, bad nutrition, and inactivity.
Moreover, anorexiants, a type of anti-obesity drugs, are recommended for a limited number of adults due to safety concerns. These medications work by targeting the limbic parts of the brain that control satiety, thereby suppressing appetite. Hence, the above factors will impede the growth of the market during the forecast period.
The market forecasting report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
Epic Pharma LLC: The company offers anorexiants that is an appetite suppressant that affects the central nervous system.
The market research and growth report also includes detailed analyses of the competitive landscape of the market and information about key companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
The hospital pharmacy segment is estimated to witness significant growth during the forecast period. Weight loss medications, in the form of drugs, play a significant role in managing obesity and associated health conditions such as cardiovascular diseases, diabetes, and hypertension. Pharmaceutical compounds used for weight loss include catecholamines anorexiants, which stimulate the nervous system to reduce appetite, and serotonin anorexiants, which affect the brain's hunger signals.
Get a glance at the market share of various regions Download the PDF Sample
The hospital pharmacy segment was the largest segment and valued at USD 2.14 billion in 2018. These medications are available in various forms, including tablets and capsules, for oral administration or subcutaneous injection. Sedentary lifestyles, physical inactivity, and unhealthy dietary habits contribute to the rising prevalence of obesity. The World Health Organization (WHO) reports that over 1.9 billion adults are overweight, and of these, over 650 million are obese. The use of weight loss medications is increasing among children and adolescents, as well as the geriatric population, to manage weight-related health issues. Hence, such factors are fuelling the growth of this segment during the forecast period.
For more insights on the market share of various regions Download PDF Sample now!
North America is estimated to contribute 52% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period. Anorexiants, also known as weight loss medications, play a significant role in managing obesity and associated health conditions such as cardiovascular diseases, diabetes, and hypertension. These drugs contain various pharmaceutical compounds that work by suppressing appetite or increasing metabolism. Sedentary lifestyles, physical inactivity, and unhealthy dietary habits contribute to the rising prevalence of obesity, making anorexiants essential therapeutics. The World Health Organization recognizes the importance of addressing obesity, leading to the development of various anorexiants, including subcutaneous and oral forms. Hence, such factors are driving the market in North America during the forecast period.
The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD billion " for the period 2024-2028, as well as historical data from 2018 - 2022 for the following segments.
You may also interested in below market reports:
Overcoming Obesity and Related Health Conditions with Weight Loss Medications Anorexiants, also known as appetite suppressing medications, are a crucial segment of weight loss treatments. These drugs, comprised of pharmaceutical compounds, aid individuals in managing their weight by decreasing hunger and increasing feelings of fullness. Sedentary lifestyles, physical inactivity, and unhealthy dietary habits have led to an alarming rise in obesity, which in turn fuels the demand for anorexiants. Some side effects include Nausea, Vomiting, Mortality, Adherence rates, Epidemiology, and Appetite suppressants. Conditions such as cardiovascular diseases, diabetes, and hypertension, closely linked to obesity, further necessitate the use of anorexiants. The World Health Organization (WHO) reports that over 1.9 billion adults were overweight in 2016, and 650 million were obese. Anorexiants come in various forms, including tablets and capsules, and are administered through online pharmacies, retail pharmacies, and hospitals.
Moreover, two main categories of anorexiants are catecholamines anorexiants and serotonin anorexiants. The former stimulates the sympathetic nervous system, while the latter affects the brain's serotonin levels. Subcutaneous and oral anorexiants are available, catering to diverse patient needs. Anorexiants are also used to treat conditions like ADHD, Dravet Syndrome, and Lennox Gastaut Syndrome. The therapeutics are particularly essential for children and adolescents and the geriatric population. Skilled professionals, including doctors and pharmacists, play a significant role in prescribing and administering these medications. Binge eating disorder, a common eating disorder, is another area where anorexiants can be beneficial. By targeting the hypothalamus, these medications can help regulate appetite and promote weight loss. The market for anorexiants is expected to grow significantly due to the increasing prevalence of obesity and related health conditions.
Market Scope |
|
Report Coverage |
Details |
Page number |
138 |
Base year |
2023 |
Historic period |
2018 - 2022 |
Forecast period |
2024-2028 |
Growth momentum & CAGR |
Accelerate at a CAGR of 4.5% |
Market growth 2024-2028 |
USD 1.02 billion |
Market structure |
Fragmented |
YoY growth 2023-2024(%) |
4.23 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 52% |
Key countries |
US, Canada, UK, Germany, and Japan |
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Key companies profiled |
Bausch Health Companies Inc., Currax Pharmaceuticals LLC, Elite Pharmaceuticals Inc., Epic Pharma LLC, F. Hoffmann La Roche Ltd., Hi Tech Pharmaceuticals, Intas Pharmaceuticals Ltd., Johnson and Johnson Services Inc., KVK Tech Inc., Lannett Co. Inc., Novartis AG, Novo Nordisk AS, Pfizer Inc., Recordati S.p.A, Searchlight Pharma Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Virtus Nutrition LLC, VIVUS LLC, and Zydus Lifesciences Ltd. |
Market dynamics |
Parent market analysis, market report, market forecast, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Distribution Channel
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Opportunity/Restraints
10 Competitive Landscape
11 Competitive Analysis
12 Appendix
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.